Inflectra Market Report 2026

Inflectra Market Overview

• The Inflectra market growth in the historic period has been driven by high cost of originator tnf inhibitors, regulatory biosimilar approvals • Market expansion is supported by biosimilar friendly regulations, expanding patient access to biologics • Growth Driver: Rising Autoimmune Disease Prevalence Fuels Demand For Inflectra As A Key Treatment Option • Market Trend: Innovative Subcutaneous Infliximab Simplifies Treatment For Inflammatory Bowel Disease • Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Inflectra Market?

Inflectra, generically known as infliximab-dyyb, is a biosimilar to Remicade (infliximab) and is classified as a tumor necrosis factor (TNF) inhibitor. It is commonly used to treat various autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. It is a monoclonal antibody that specifically targets and inhibits TNF-alpha, a key pro-inflammatory protein involved in immune responses. The main patient demographics of inflectra involved are pediatric patients and adult patients. Pediatric patients are children and adolescents under the age of 18 who may suffer from autoimmune diseases like Crohn's disease or ulcerative colitis. The various application involved are rheumatoid arthritis, crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and others. The various distribution channel involved are hospitals, specialty clinics, online pharmacies, and retail pharmacies.

What Is The Inflectra Market Growth Forecast?

The growth in the forecast period can be attributed to biosimilar friendly regulations, expanding patient access to biologics, growth in inflammatory diseases, competitive pricing pressure, increasing physician familiarity. Major trends in the forecast period include rising adoption of biosimilars, cost driven switching from originator biologics, expansion of autoimmune disease treatment, physician confidence in biosimilar safety, hospital led biosimilar procurement.

Global Inflectra Market Segmentation

1) By Patient Demographics: Pediatric Patients, Adult Patients 2) By Application: Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Other Indications 3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies

What Are The Drivers Of The Inflectra Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the inflectra market going forward. Autoimmune diseases are conditions in which the immune system mistakenly attacks healthy cells, leading to inflammation and damage to various tissues and organs. The prevalence of autoimmune diseases is due to changes in diet, exposure to pollutants, lifestyle behaviors, and climate change. The autoimmune diseases impact inflectra by increasing demand for effective treatment options, as more patients seek therapies such as inflectra, which is crucial for managing conditions such as rheumatoid arthritis and Crohn's disease by blocking tumor necrosis factor-alpha (TNF-α) to reduce inflammation. For instance, in September 2023, according to the IBD Clinical and Research Centre, a Canada-based organization that aims to improve the lives of patients with Crohn's disease and ulcerative colitis, 2023 over 320,000 Canadians live with inflammatory bowel disease (IBD) with a prevalence of 825 per 100,000. As the prevalence rises by 2.44% annually, 1.1% of Canada's population, or 470,000 people, is projected to have IBD by 2035. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the inflectra industry. A growing number of clinical trials is expected to propel the growth of the inflectra market going forward. Clinical trials are research studies that involve human participants to evaluate the effects of new medical interventions, including drugs, devices, and behavioral treatments, on health outcomes, and they are essential for determining the safety and efficacy of these interventions before they can be approved for widespread clinical use. The increasing number of clinical trials can be attributed to the growing demand for innovative treatments and therapies, driven by advancements in medical research, the need for diverse participant representation, and the urgency to address unmet medical needs across various populations. The increasing number of clinical trials is impacting inflectra by generating robust data on its efficacy and safety, which enhances its market positioning and drives demand as a treatment option for autoimmune diseases. For instance, in April 2025, according to a National Library of Medicine, a US-based government agency, as of March 2025, 404,637 interventional clinical trials were listed on ClinicalTrials.gov, with 27,751 new trials launched in 2023. Therefore, the growing number of clinical trials is driving the growth of the inflectra industry.

Key Players In The Global Inflectra Market

Major companies operating in the inflectra market are Celltrion Inc

Global Inflectra Market Trends and Insights

The key trend in the inflectra market is focusing on developing innovative products, such as subcutaneous infliximab biosimilars, to provide a convenient, effective maintenance treatment option for inflammatory bowel disease patients with a subcutaneous formulation. Subcutaneous infliximab biosimilar is an injectable form of infliximab that offers a more convenient administration method for treating autoimmune diseases. For instance, in October 2023, Celltrion USA, a US-based subsidiary of Celltrion, a biopharmaceutical company, announced the FDA approval of ZYMFENTRA (infliximab-dyyb), the first and only subcutaneous formulation of infliximab for the maintenance treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC) in adults. This novel subcutaneous formulation delivers stable elevated serum infliximab levels, providing a more convenient and flexible administration option for patients and healthcare providers. The approval is significant as it addresses the day-to-day burden of managing inflammatory bowel disease and enhances patient control over their treatment regimen.

Regional Insights

Europe was the largest region in the inflectra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Inflectra Market?

The inflectra market consists of sales of lyophilized powder and intravenous infusion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inflectra Market Report 2026?

The inflectra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inflectra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.